Prebiotics for people with cystic fibrosis

Williams, Neil; Jayaratnasingam, Jacob; Prayle, Andrew P; Nevitt, Sarah J; Smyth, Alan R

Abstract

Background. Description of the condition. Cystic fibrosis (CF) is a life‐limiting genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It affects approximately 100,000 children and adults worldwide (Bell 2020). CF is a multisystem disease resulting in thick secretions predominantly affecting the lungs, gastrointestinal (GI) tract, pancreas and liver. Around 84% of people with CF have exocrine pancreatic insufficiency, requiring treatment with pancreatic enzyme replacement therapy (PERT) (Cystic Fibrosis Foundation Patient Registry 2020). In spite of treatment with PERT, many people have frequent GI symptoms (Smith 2020). Children with CF may struggle to gain weight adequately and adults may have difficulty maintaining a healthy weight (Stallings 2008). The growth and nutritional status of people with CF is important as they are major determinants of lung function and survival (Corey 1988; Jadin 2011). Around half of people with CF achieve an adequate nutritional status (McCormick 2010; Turck 2016); and many children with CF fail to achieve catch‐up weight gain. However, a new era of CF care has increased lifespan and decreased symptoms in many people with CF, necessitating a re‐examination of the legacy diets in CF (McDonald 2021).

Citation

Williams, N., Jayaratnasingam, J., Prayle, A. P., Nevitt, S. J., & Smyth, A. R. (2022). Prebiotics for people with cystic fibrosis. Cochrane Database of Systematic Reviews, 2022(12), Article CD015236. https://doi.org/10.1002/14651858.cd015236

• Journal Article Type: Review
• Acceptance Date: Dec 16, 2022
• Online Publication Date: Dec 16, 2022
• Publication Date: Dec 16, 2022
• Deposit Date: Apr 22, 2023
• Publicly Available Date: Dec 17, 2023
• Journal: Cochrane Database of Systematic Reviews
• Electronic ISSN: 1469-493X
• Publisher: Cochrane Collaboration
• Peer Reviewed: Peer Reviewed
• Volume: 2022
• Issue: 12
• Article Number: CD015236
• DOI: https://doi.org/10.1002/14651858.cd015236
• Keywords: Pharmacology (medical)
• Public URL: https://nottingham-repository.worktribe.com/output/15431429
• Publisher URL: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015236/full
• Additional Information: Williams N, Jayaratnasingam J, Prayle AP, Nevitt SJ, Smyth AR. Prebiotics for people with cystic fibrosis (Protocol). Cochrane Database of Systematic Reviews 2022, Issue 12. Art. No.: CD015236. DOI: 10.1002/14651858.CD015236.